* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
Reverse Takeovers: Potentially AI (AGI.L), the collective AI Company, announced the completion of its reverse takeover of Tiger Alpha (TIR.L) and its re-admission to trading on AIM. Alongside its re-admission, Potentially has successfully raised approximately £4.9m with a market cap of c£19.1m. The proceeds of this fundraising will be used to fund Potentially's product and technology development, commercial growth and working capital. Potentially was founded by Oliver Yonchev and Sukhveer Sanghera and was incorporated in Cyprus in 2025. It has built a unified creative platform that allows users to create, protect and monetise digital content using artificial intelligence.
Delistings:
None
What’s baking in the oven?
It's a little empty
Banquet Buffet****
London Stock Exchange: Main Market and AIM
Acuity RM Group 0.75p £2.22m (ACRM.L)
The software group specialising in the cybersecurity sector of the Governance, Risk and Compliance market announces the first sale of its new STREAM Cloud multi-tenant platform. The sales is to a leading provider of funeral services operating throughout the UK. The client is using STREAM
Cloud to comply with a well-known security framework, and digitise its existing, bespoke risk management processes. There will be an increase in sales and marketing investment following the Company's recent equity fundraise. The Board views this win as an early indicator of the potential success this product can deliver.
Aptamer Group 0.48p £16.41m (APTA.L)
The developer of next-generation synthetic Optimer binders updates on Trading for the FY to 30 June 2026 as commercial progress is being made with revenue growth. Revenue is expected to be 25% higher at £1.5m and the sales pipeline has increased 55% to £4.8m. The first licensing revenues have been generated, marking an important milestone towards higher-margin licensing income. Investment is continuing in the Group's AI-enabled discovery platform, to automate the internal therapeutic pipelinesupporting future value creation. Following the April 2026 fundraise, the cash runway is into at least 2028, supporting continued execution of the commercial and development strategy. The Group is well positioned, according to the CEO, to continue its progress.
Cobra Resources 4.25p £44.52m (COBR.L)
The South Australian mineral exploration and development Company updates on observations from the latest four-hole, 1,465m programme of diamond core drilling at the Manna Hill Copper Project. The programme phase was designed to test for extensions of the shallow, high-grade copper-gold mineralisation recently discovered at the Blue Rose prospect while also evaluating the potential for a deeper intrusive-related porphyry copper system. The geological observations provide encouraging indicators of an extensive and fertile porphyry system, while the diamond drilling provides a greater understanding of the structural and geological control. This will enable a refined drilling programme to optimise outcomes. Before the laboratory results are received, the Company will formally exercise its option to acquire Manna Hill and is now progressing two significant South Australian projects in parallel.
Genedrive 1.23p £20.47m (GDR.L)
The point of care pharmacogenetic testing Company updates on trading update for FY to 30 June 2026. Revenue of around £1.4m for FY26 is inline with expectations and compares to £1.0m, reflecting commercial momentum and operational progress across the business. International revenue is expected to contribute approximately one quarter of total income. The Company completed an equity raise in March 2026, which raised net proceeds of around £4.9m. The unaudited cash position as of 30 June 2026 was c.£3.0m, and the monthly cost base is approximately £0.5m. The Board remains encouraged by increasing clinical adoption of both the Genedrive CYP2C19 and MT-RNR1 ID Kits, the growing evidence base supporting point-of-care pharmacogenetic testing, and the continued progress towards wider NHS implementation an the long-term opportunity for both products.
Ixico 8.00p £20.26m (IXI.L)
The neuroscience imaging and biomarker analytics Company using its AI-driven platform to help advance drug development and diagnostics in neurological disorders notes the continued evolution of the Huntington's disease (HD) landscape which is an area of particular interest. At the Interims, IXICO secured £8.0m of new HD programme awards by new and existing clients, however since then two existing HD programmes have been discontinued by their sponsors, reducing the Company's contracted order book by around £1.5m over the next two financial years. Following these changes, IXICO's order book remains 21% above the FY25 year-end level which is a solid increase. The Board confirms that its recently upgraded FY26 and its FY27 revenue guidance remain unchanged and continues to expect the Company to meet or exceed market expectations.
Nativo Resources 0.23p £2.31m (NTVO.L)*
The precious metals Company with gold mining and processing interests in Peru updates on the development plan for the La Patona Gold Ore Processing Plant (GOPP). This is in Acarí, approximately 45 km from the Company's wholly owned Tesoro Gold Concession. Following completion of front-end engineering design, detailed line-item capital costings and production modelling, the Company has re-sequenced the development of GOPP into three phases. This is designed to optimise capital deployment, accelerate time to first revenue and reduce scale-up risk. The final investment decision for Phase 1 is subject to the completion of project financing and there are advanced financing discussions with multiple potential funding partners. There is an offtake proposal from a major commodities trading house under consideration. Once funded, the Company will commit to Phase 1, with construction and commissioning targeted for H2 2026 and first gold production targeted in Q4 2026.
Pennant International Group 29.50p £13.34m (PEN.L)
The systems support software and training solutions provider updates on trading for the six months ended 30 June 2026. Revenues are expected to be 31% ahead at c.£5.9m as there are increased levels of activity on contracted Engineered Training programmes and the virtual training simulator. The ARR should be £2.6m and gross profit margins have increased to 53% from 45%. An EBITDA of £0.5m is expected and compares to a loss £1.0m. The loss before tax is set to declines to £0.3 against £1.7m in the prior period, with continued investment of £0.7m in the Auxilium suite. H1 net debt at was £0.9m against £1.0m in the prior period. The Company is on track to achieve full year 2026 market expectations of £13.0m revenue, an EBITDA of £1.6m and break even with debt of £0.5m. In 2027, a PBT of £0.6m is expected on £14.5m turnover and debt of £0.1m.
Sabien Technology Group 3.25p £1.03m (SNT.L)
The provider of energy efficiency technologies through its M2G intelligent boiler optimisation platform updates on trading for the FY to 30 June 2026. Revenue is expected to be around £0.75m compared to £0.85m in the prior period, although there are confirmed customer orders of over £196,000, compared with £59,453 in the prior period. The focus is on transforming Sabien into a higher-margin technology business centred on its M2G Cloud Connect platform, whilst strengthening its balance sheet and evaluating strategic opportunities to accelerate long-term shareholder value. The strategic review included discussions regarding potential strategic investment and commercial partnership opportunities intended to accelerate deployment of the M2G platform and support the Company's long-term growth strategy. These discussions remain ongoing although there is no certainty that any transaction will ultimately proceed.
Zinc Media Group 57.50p £17.17m (ZIN.L)
The international content creation group launches Cicada, a new AI label that will drive AI innovation across the Group and empower Zinc's production of commercials, films, events and content for clients. Cicada will strengthen Zinc's wider operating platform across client services, production, post-production, marketing and internal delivery. By embedding these tools across the business, Zinc expects to enhance creative capability, improve workflow efficiency and support margin growth across its labels. The launch supports the stated strategy of scaling high-margin growth areas and reinforces the Group's progress towards its medium-term targets of £50m revenue and £5m EBITDA.
AQSE Market
Incanthera 2.00p £3.03m (AQSE:INC)
The Company focused on innovative technologies in dermatology and oncology provides a Corporate Update and notes Board changes. Incanthera has completed the acquisition of the énielle assets and is now working on the integration. This will promote a single skincare "protect + repair" routine covering both products. There are also three Board appointments with Ms. Laura Brogden as Executive Chief Financial Officer, Mr. Werner Bürki as a Non-executive Director and Ms. Caroline Murray as its new Non-executive Chair. The CEO states that this is the first in a series of announcements as the Company becomes a leaner and more focussed sales and stakeholder centric global business delivering science-led, best-in-class products that improve skin health.What’s baking in the oven?
What’s baking in the oven?
Potential IPOs:***
Dual List:***
Bravura Solutions (ASX: BVS) the global provider of enterprise software for the wealth management and funds administration industries has announced its intention to dual list on AIM. Bravura is currently listed on the Australian Securities Exchange (ASX) and Admission to AIM is being sought via the AIM Designated Market Route. No capital to be raised on Admission with a market cap on Admission of circa £500m. Expected Admission date is 28 July.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
